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Letters to the Editor 
HALOPERIDOL DECANOATE : ROUTE OF AD-
MINISTRATION 
Sir, 
Haloperidol decafloate (HPL-D) is a useful 
depot neuroleptic on several counts : it has a dura-
tion of action of 4-6 weeks, there is no dumping ef-
fect associated with its administration, and the ad-
verse effects milligram for milligram are fewer and 
milder than those observed with the oral form of 
haloperidol (Beresford and Ward, 1987, Glazer and 
Kane, 1992). 
HPL-D requires to be administered by deep 
intramuscular injection; subcutaneous administra-
tion may be associated with the development of in-
jection site reactions (Hamann et al., 1990). In low 
doses, intramuscular administration into the deltoid 
is feasible and convenient. In high doses, however, 
the larger volume of drug to be administered ne-
cessitates injection into the gluteus. 
This is where the problem arises. Disposable 
syringes in India usually have an approximately one 
inch needle length. Disposable 21 gauge needles, 
required for use with HPL-D, are generally of the 
same length. Consttutional and behavioural factors, 
more in women than in men, usually result in the 
presence of gluteal fat that is over an inch or two in 
thickness in the average Indian patient. In conse-
quence, it is likely that despite gluteal compression 
during injection, few Indian patients truly receive 
deep intramuscular HPL-D when the drug is injected 
into the buttock, in fact, it is possible that many pa-
tients are actually receiving the injection in subcu-
taneous fat. 
No reports of injection site reaction with HPL-
D have appeared in the Indian scientific press. Is 
this because of under-reporting or might subcuta-
neous HPL-D be less harmful than earlier 
believed ? 
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STRESS, DEPRESSION AND GENOMIC CHANGE 
Sir, 
Deregulation of hypothalamo- pituitary ad-
renal axis (HPA) is one of the oldest and most con-
sistent findings in depression. It is now generally 
accepted that stressful life events and chronic diffi-
culties can trigger the onset of depression in pre-
disposed individuals. Enough is known about the 
central control of HPA function and its response to 
stress in the neurobiology of triggering the depres-
sion. The stress induces hypercortisolaemia which 
triggers depression by inducing genomic change. 
There are two types of corticoid receptors in brain 
tissue - type I and type II receptors (Reul & De Kloet, 
1986). Under basal conditions Cortisol has very high 
affinity with 80% occupancy of type I receptors 
whereas type II receptors are occupied and acti-
vated only during stress (Ratka, 1989). Further, hip-
pocampus is the most vulnerable site for the 
neurotoxic action of glucocorticoids The 
glucocorticoid recepters are predominandy present 
in hippocampal area. Of late, in vivo hippocampal 
atrophy assessed using magnetic resonance imag-
ing has been correlated with plasma Cortisol levels 
in depression (Axelson et al., 1993) A related but 
astonishing fact is that all hormones with weH de-
fined effects on mood (estrogen, progesterone, 
glucocorticoids and thyroxine) have intraceRuar re-
ceptors whereas most other hormones act through 
membrane receptors. More surprising than this is 
that these intracellular receptors have two 
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aminoacid sequences in common which are thought 
to bind hormones to specific sequences of DNA and 
modify the gene transcription (Beato, 1989). The 
complex formed by the binding of a steroid with a 
receptor is translocated into the cell nucleus where 
it binds to DNA and influences the expression of 
genes So the activation in depression of the HPA 
axis involves various steps in producing excess Cor-
tisol and then inducing genomic change. The block-
ade at each one of them is being targeted to an-
tagonise the effects of stressful life events in pro-
ducing depression or in the treatment of depression. 
The therapeutic potential of antiglucocorticoid drugs 
especially type II receptor antagonists and steroid 
synthesis inhibitors have been explored with encour-
aging results in patients with mood disorders 
(Mitchell & O'Keanne, 1998). 
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TREATMENT BY IMIPRAMINE OF DEAFNES8 
AND DEPRESSION 
Sir, 
I would like to share one of my experience 
while treating a patient suffering from major depres-
sion with deafness. 
Mr. PCJ aged about 44 years, a cterk in NCC 
came to consult in June 97 with one year history of 
decreased interest in family, work & social activi-
ties, sleep and appetite. Interview was difficult as 
he was hard of hearing from both ears. With what-
ever communication possible by shouting at his right 
ear, he was found to be depressed, had ideas of 
hopelessness, worthlessness & a misfit in the 
present set up. He occasionally had ideas of end-
ing his life. 
He was prescribed Imipramine 75 mg per 
day, alprazolam 0.5 mg twice daily and 
advised to see an ENT specialist. He came back 
after 20 days with a relative and treatment records 
of his deafness. He had bilateral hearing impair-
ment for last 15 years, more marked on the left side. 
Clinically he was diagnosed as having "healed oti-
tis media with adhesive otitis media left". Audiogram 
revealed that patient had severe degree of conduc-
tive type of hearing loss in both ears more marked 
on left side. He was referred to neurosurgeon who 
advised CT scan head which was not done. 
Dejected Mr. PCJ came back having lost all 
hopes of hearing again. Meanwhile, dosage of imi-
pramine was subsequently increased to 125 mg per 
day. Over a period of few weeks his depression 
started lifting up. After 8-10 weeks when he came 
for review I was surprised to know that he could 
hear from both the ears. Hearing improved to the 
extent that he could converse on phone, could sense 
boiling of water from a distance of 3-4 feet. 
Weather this deafness was present to a 
minimum extent and got increased with 
depression or there was any relationship between 
the two cannot be commented upon with any 
certainty but what is sure that the deafness 
improved with imipramine. 
May be this experience of mine, stimulates 
few to explore the role of imipramine in treating 
such type of deafness? 
V.K. SRIVASTAVA, Psychiatrist, Mental Hospital, 
Bareilly. 243 005 (UP). 
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